Companies · Pharma

Vibliome Therapeutics, Llc

BOZEMAN · Pharma · refined from filed group “Other

Diligence memoA one-page analyst read on Vibliome Therapeutics, Llc — recommendation, valuation, rhythm, risks.
$8.0M
Total raised · real
1
Rounds
Latest step-up
Top 39%
Sector rank · raised
Series A
Latest stage · inferred · Wed Feb 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Vibliome Therapeutics, Llc looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.30× the median modeled value of Series A Pharma companies in 2019–2021 (24 peers) — value vs value, same stage and era.
  • Within the normal band (130% of peer median) for its niche.
Dormant
  • Last raise 7.4 yr ago; this sector typically re-raises about every 16 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Vibliome Therapeutics, Llc behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
7.4 yr record
Peak capital year was 2019 with $8.0M across 1 filings.
Market position
ahead of 62% of Pharma peers
Capital scale is ahead of 62% of Pharma peers; modeled value is above 80% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2019: $8.0M across 1 filings.
  • Largest single filing was $8.0M on 2019-02-13.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharma

Vibliome Therapeutics, Llc is one of 310 Pharma companies tracked from BOZEMAN. By capital raised it ranks mid-pack (ahead of 62% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

pharma

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
2
Investors (latest)
2019
Year incorporated
2019-02-13
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2019-02-13 Raised $8.0M (real) Modeled valuation $248M (est)$8.0M$248MSeries A2019

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$8.0M · 2019

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$247.8M
Base estimate est.
$9.2M
Conservative case
$1.3B
Upside case
$36.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
46%
Survival probability
25% low · 63% high
1.57×/yr
Annual markup
1.97×/yr upside case
6.0 yr
Elapsed time used
7.4 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
7.4 yr
On record since
2019
First round
1
Rounds on file
How it compares to the market

Benchmarked against 310 companies in Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.2× above median
This company$8.0M
Sector median$6.4M
Latest round — vs other Series A rounds in sector (real $, this stage) 1.2× above median
This company$8.0M
Sector median$6.7M
Modeled value — vs sector median (estimate, all stages) 4.0× above median
This company$247.8M
Sector median$62.5M

Raised more than 62% of sector peers (real $). Modeled value above 80% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #6 of 24.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Comet Therapeutics, Inc. · Series A Raised $14.1M · modeled $435.3M (est)RadImmune Therapeutics, Inc. · Series A Raised $13.6M · modeled $420.0M (est)Nanoscope Therapeutics, Inc. · Series A Raised $12.8M · modeled $393.3M (est)ZebiAI Therapeutics, Inc. · Series A Raised $10.0M · modeled $309.7M (est)Blue Note Therapeutics, Inc. · Series A Raised $13.0M · modeled $309.4M (est)Feel Therapeutics, Inc. · Series A Raised $14.1M · modeled $230.2M (est)Nextgen Pharma Llc · Series A Raised $9.0M · modeled $229.7M (est)Radiance Therapeutics, Inc. · Series A Raised $18.7M · modeled $228.3M (est)Cyprium Therapeutics, Inc. · Series A Raised $7.0M · modeled $210.1M (est)Solace Therapeutics Inc · Series A Raised $28.4M · modeled $202.2M (est)Metavir Therapeutics, Inc · Series A Raised $7.5M · modeled $197.2M (est)Vibliome Therapeutics, Llc (this company) Raised $8.0M · modeled $247.8M (est)Vibliome Therapeutics, Llc
CompanyStageRaised · realValue · estvs peer med.
Comet Therapeutics, Inc.Series A$14.1M$435.3M2.28×
RadImmune Therapeutics, Inc.Series A$13.6M$420.0M2.20×
Nanoscope Therapeutics, Inc.Series A$12.8M$393.3M2.06×
ZebiAI Therapeutics, Inc.Series A$10.0M$309.7M1.62×
Blue Note Therapeutics, Inc.Series A$13.0M$309.4M1.62×
Vibliome Therapeutics, Llc this companySeries A$8.0M$247.8M1.30×
Feel Therapeutics, Inc.Series A$14.1M$230.2M1.20×
Nextgen Pharma LlcSeries A$9.0M$229.7M1.20×
Radiance Therapeutics, Inc.Series A$18.7M$228.3M1.19×
Cyprium Therapeutics, Inc.Series A$7.0M$210.1M1.10×
Solace Therapeutics IncSeries A$28.4M$202.2M1.06×
Metavir Therapeutics, IncSeries A$7.5M$197.2M1.03×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$8.0M2019-02-13$36.4M$247.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$8.0M2019-02-13
    • First recorded raise — entered as Series A.
    • 2 investors on this round.
Intelligence
Modeled next raise
$12.8M
Modeled next size est.range $8.3M$20.5M
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Cameron Wheeler8 other2019-02
MICHAEL FARRELL5 other2019-02
Bryan Sendrowski2 other2019-02
Robert Goodwin2 other2019-02
ROBERT JACKSON2 other2019-02
GARY FLYNN1 other2019-02
Jonathan Ramos1 other2019-02
Registry & provenance

Vibliome Therapeutics, Llc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1768843
SEC CIK
2019
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Humanity Health, Inc.HealthtechSeries A$9.0M$94.5Mnetwork2 shared operators · same stage
Vibliome Therapeutics, Inc.PharmaPre-Seed$113K$5.3Mnetwork2 shared operators · same sector
AffyImmune Therapeutics, Inc.PharmaSeries A$7.9M$243.4Msame sector · same stage
Luxvitae Therapeutics Inc.PharmaSeries A$8.5M$36.7Msame sector · same stage
Monitored Therapeutics, Inc.PharmaSeries A$8.5M$82.4Msame sector · same stage
Metavir Therapeutics, IncPharmaSeries A$7.5M$197.2Msame sector · same stage
Violet Therapeutics, Inc.PharmaSeries A$7.4M$65.7Msame sector · same stage
Cello Therapeutics, Inc.PharmaSeries A$8.7M$85.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Vibliome Therapeutics, Inc.PharmaPre-Seed$5.3M99%
Virion Therapeutics, LLCBiotechnologySeries A$205.0M83%
Viridian Therapeutics, Inc.BiotechnologySeries B$978.3M81%
NV Therapeutics, Inc.PharmaSeed$12.8M81%
Viracta Therapeutics, INC.BiotechnologySeries C$2.1B81%
vTv Therapeutics Inc.PharmaceuticalsSeries C$502.3M80%
Vitruvias Therapeutics, Inc.PharmaceuticalsSeries A$356.2M80%
King Therapeutics LLCPharmaPre-Seed$807K80%
Frequently asked
How much funding has Vibliome Therapeutics, Llc raised?
Vibliome Therapeutics, Llc has raised approximately $8.0M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Vibliome Therapeutics, Llc's estimated valuation?
Provath's modeled valuation for Vibliome Therapeutics, Llc is approximately $247.8M (modeled range $9.2M–$1.3B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Vibliome Therapeutics, Llc at?
Vibliome Therapeutics, Llc's latest modeled financing stage is Series A. Its most recent recorded round closed around Wed Feb 13.
What does Vibliome Therapeutics, Llc do and where is it based?
Vibliome Therapeutics, Llc operates in the Pharma sector, based in BOZEMAN.
Explore related

See where Vibliome Therapeutics, Llc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Vibliome Therapeutics, Llc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.